By Chris Wack
AbbVie said it saw continued positive results from a four-year follow-up analysis of its Phase 3 CLL14 trial.
The pharmaceutical company said the trial showed that previously untreated patients with chronic lymphocytic leukemia with coexisting conditions who were treated with Venclyxto/Venclexta venetoclax plus obinutuzumab continued to show longer progression-free survival and higher rates of undetectable minimal residual disease compared to patients receiving a standard of care chemoimmunotherapy regimen of obinutuzumab and chlorambucil.
"The CLL14 trial results observed after four years of follow-up with treatment of venetoclax plus obinutuzumab show that these patients can experience long-lasting responses without disease progression, years after stopping treatment," said Mohamed Zaki, vice president and head of global oncology development at AbbVie.
After a median follow-up of more than four years, patients treated with the Venclyxto/Venclexta and obinutuzumab combination continued to demonstrate longer progression free survival compared to patients on treatment with obinutuzumab and chlorambucil, and the risk of disease progression or death was reduced by 67%.
No new safety signals were observed in the four-year follow-up analysis. The most frequently occurring serious adverse reactions in patients receiving venetoclax in combination with obinutuzumab were pneumonia, sepsis, febrile neutropenia, and TLS.
Venclyxto/Venclexta is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S.
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires